mRNA vaccine boosters and procurement strategies for potential variant specific vaccines: Standing Committee on Health—January 18, 2022

Document navigation for "Standing Committee on Health: January 18, 2022"

Procurement of COVID-19 vaccines


Public Services and Procurement Canada (PSPC) is working with the Public Health Agency of Canada, Health Canada and Innovation, Science and Economic Development Canada (ISED), along with the COVID-19 Vaccine Task Force to procure COVID-19 vaccines, therapeutic drugs, and related supplies.



Suggested response

If pressed on additional pediatric vaccines:

If asked on delivery of pediatric doses for children:

If pressed on future Pfizer supply:

If pressed on future Moderna supply:

If pressed on the release of vaccine contracts:

If pressed on the details of advance purchase agreements:


Overall, the federal government has allocated over $9 billion for vaccine procurement and Public Health Agency of Canada is responsible for managing this funding.

Currently, Pfizer, Moderna, AstraZeneca and Johnson & Johnson have been approved to prevent COVID-19. Medicago and Novavax have sent their final submission to Health Canada and are waiting for approval. Sanofi started the regulatory submission process for its primary COVID-19 vaccine. Through this process Health Canada will review the evidence of safety, efficacy, and manufacturing quality for each vaccine to determine whether individual vaccines will be approved for use in Canada, before they are used to vaccinate Canadians.

The Government of Canada has signed agreements in principle with the following companies to obtain access to their vaccines and vaccine candidates:

Other key issues:

Key points vaccine portfolio

Procurement strategies for variant-specific vaccines


Future Pfizer supply:

Future Moderna supply:

Domestic manufacturing capacity of vaccines

Document navigation for "Standing Committee on Health: January 18, 2022"

Date modified: